Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
Descriptor ID |
D000806
|
MeSH Number(s) |
D27.505.519.389.745.085
|
Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
1997 | 0 | 1 | 1 |
1998 | 0 | 2 | 2 |
2001 | 0 | 1 | 1 |
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 2 | 1 | 3 |
2005 | 1 | 2 | 3 |
2006 | 1 | 1 | 2 |
2008 | 2 | 0 | 2 |
2010 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. Crit Care Med. 2022 10 01; 50(10):e744-e758.
-
The Role of Polymers and Excipients for Better Gastric Retention of Captopril. Crit Rev Ther Drug Carrier Syst. 2022; 39(6):85-106.
-
Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. Int J Mol Sci. 2021 Oct 28; 22(21).
-
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat Commun. 2020 10 28; 11(1):5453.
-
Whey-Derived Peptides Interactions with ACE by Molecular Docking as a Potential Predictive Tool of Natural ACE Inhibitors. Int J Mol Sci. 2020 Jan 29; 21(3).
-
Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data. J Comp Eff Res. 2018 11; 7(11):1073-1082.
-
Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. Am J Epidemiol. 2018 08 01; 187(8):1799-1807.
-
Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail. 2012 Jan-Feb; 18(1):9-17.
-
Question: Should patients who have a significant increase in BUN or creatinine (more than 30% above baseline) in response to an ACEI or ARB be tested for renal stenosis? J Okla State Med Assoc. 2010 Nov-Dec; 103(11-12):545-6.
-
Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail. 2010 Sep; 3(5):596-605.